Plasmodium malariae infection - Symptoms, Causes, Treatment & Prevention

Overview

Plasmodium malariae is one of the five Plasmodium species that cause malaria in humans. Unlike the more common P. falciparum and P. vivax, P. malariae typically produces a milder, chronic infection that can persist for years if untreated. The parasite is transmitted through the bite of an infected female Anopheles mosquito.

Who it affects: The infection occurs worldwide in tropical and subtropical regions, but it is most prevalent in parts of sub‑Saharan Africa, the western Pacific, and some areas of South America. It is less common than P. falciparum, accounting for < 5 % of malaria cases globally, but it remains a public health concern because of its potential for long‑term complications.

Prevalence (World Health Organization, 2023):

• Estimated 15–20 million malaria cases annually are caused by non‑falciparum species; of these, P. malariae contributes roughly 1–2 million cases.
• Endemic countries with documented transmission include Nigeria, Democratic Republic of Congo, Papua New Guinea, and parts of the Amazon basin.
• In regions with strong malaria control programs, P. malariae infections have declined, yet sporadic outbreaks still occur, especially in remote or conflict‑affected areas.

Symptoms

The clinical picture of P. malariae infection can range from asymptomatic to a classic “quartan fever” pattern (fever spikes every 72 hours). Symptoms usually appear 18–40 days after the infective bite, but the parasite can remain in the blood at low levels for years.

Typical signs and their descriptions

• Fever with a 72‑hour cycle (quartan fever) – The hallmark pattern; chills and shivering precede a high‑temperature episode that recurs every third day.
• Headache – Often dull, worsening during fever peaks.
• Chills and rigors – Intense shaking chills that accompany the rise in temperature.
• Muscle and joint aches – Generalized myalgia, sometimes mistaken for viral illness.
• Fatigue – Persistent tiredness that may linger after the acute phase.
• Nausea, vomiting, and loss of appetite – Gastrointestinal upset is common during febrile episodes.
• Sweating – Profuse sweat as fever resolves.
• Anemia – Mild to moderate due to destruction of infected red blood cells; may cause pallor, especially in children.
• Splenomegaly – Enlargement of the spleen, noted on physical exam in chronic cases.
• Jaundice – Rare, occurs when hemolysis is significant.

In some individuals, especially adults living in endemic areas, infection can be completely asymptomatic, making detection reliant on laboratory screening.

Causes and Risk Factors

What causes infection?

P. malariae is acquired when an infected Anopheles mosquito injects sporozoites into the bloodstream during a blood meal. The sporozoites travel to the liver, develop into schizonts, and then release merozoites that infect red blood cells. Unlike P. vivax and P. ovale, P. malariae does not form dormant liver hypnozoites, but it can persist at low parasitemia for decades.

Key risk factors

• Geographic exposure – Living in or traveling to endemic regions without proper prophylaxis.
• Poor housing or lack of window screens – Increases nighttime mosquito contact.
• Pregnancy – Immunologic changes may heighten susceptibility.
• Immunocompromised state – HIV infection, organ transplantation, or chronic steroid use can exacerbate disease severity.
• Previous malaria infection – Partial immunity can mask symptoms, leading to chronic low‑grade infection.
• Occupational exposure – Forest workers, miners, and military personnel in endemic zones.

Diagnosis

Accurate diagnosis is essential because treatment differs from P. falciparum. The following tests are routinely used:

Microscopic blood smear

• Thick smear – Increases detection sensitivity; used for initial screening.
• Thin smear – Allows species identification based on characteristic band‑shaped trophozoites.
• Typical parasitemia in P. malariae is low (often <0.1 % of red cells), requiring an experienced microscopist.

Rapid Diagnostic Tests (RDTs)

Most RDTs detect Histidine‑Rich Protein‑2 (HRP2) or lactate dehydrogenase (LDH). While they reliably identify any Plasmodium infection, they are less accurate for species differentiation, especially for P. malariae. Positive RDTs should be confirmed with microscopy.

Polymerase Chain Reaction (PCR)

PCR is the most sensitive method, capable of detecting sub‑microscopic infections and distinguishing between species. It is used in reference laboratories or for epidemiologic studies.

Complete Blood Count (CBC)

Typical findings include mild anemia, thrombocytopenia, and occasional leukocytosis during febrile spikes.

Additional tests (if complications suspected)

• Renal function panel – to assess for nephrotic syndrome.
• Chest X‑ray – if respiratory symptoms develop.

Treatment Options

Treatment aims to eradicate blood‑stage parasites and prevent relapse. Because P. malariae does not have a dormant liver stage, a single‑course regimen is usually curative.

First‑line medications (per WHO 2023 guidelines)

• Chloroquine – 25 mg/kg total dose given over three days (10 mg/kg on day 1, then 10 mg/kg on day 2, 5 mg/kg on day 3). Effective in >95 % of cases where resistance is absent.
• Alternative: Artemisinin‑based Combination Therapy (ACT) – Recommended in regions with documented chloroquine resistance. Common regimens:
  • Artemether‑lumefantrine (20 mg/120 mg) twice daily for 3 days.
  • Dihydroartemisinin‑piperaquine once daily for 3 days.

Severe or complicated infection

Although rare with P. malariae, severe disease (e.g., renal failure) warrants intravenous therapy:

• IV artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until able to tolerate oral medication.
• Follow-up oral ACT or chloroquine to complete the course.

Supportive care

• Fluid management – careful monitoring to avoid volume overload, especially in renal involvement.
• Fever control – acetaminophen or ibuprofen as needed.
• Blood transfusion – for severe anemia (<7 g/dL) or symptomatic patients.

Lifestyle & follow‑up

Patients should have a repeat blood smear 48–72 hours after treatment to confirm parasite clearance and a final check at 4 weeks to rule out recrudescence.

Living with Plasmodium malariae Infection

While most infections resolve with proper therapy, some individuals develop chronic low‑grade parasitemia. Practical tips for daily management include:

• Adhere strictly to the medication schedule – Missing doses increases the risk of treatment failure.
• Maintain hydration – Helps prevent hemolysis‑related kidney strain.
• Monitor temperature – Keep a log of any febrile episodes; report recurring fevers to a clinician.
• Nutrition – Iron‑rich foods (lean meats, beans, leafy greens) support red‑blood‑cell recovery.
• Regular medical review – At least once every 6 months for people with previous P. malariae infection, especially if they travel to endemic areas again.
• Vaccination updates – Ensure routine vaccines (e.g., hepatitis B, tetanus) are current, as co‑infection can worsen outcomes.

Prevention

Preventing mosquito bites remains the cornerstone of malaria control.

Personal protective measures

• Use insecticide‑treated bed nets (ITNs) every night.
• Apply EPA‑registered repellents containing DEET (20‑30 %), picaridin, or IR3535 to exposed skin.
• Wear long‑sleeved shirts and pants, especially from dusk to dawn.
• Stay in screened or air‑conditioned rooms whenever possible.

Chemoprophylaxis for travelers

CDC recommends the following options for regions where P. malariae is present (if chloroquine‑sensitive):

• Atovaquone‑proguanil (Malarone) – one daily tablet, starting 1–2 days before travel and continuing 7 days after departure.
• Doxycycline – 100 mg daily, started 1‑2 days before travel and continued 4 weeks after return.
• Mefloquine – 250 mg weekly, started 2‑3 weeks before travel (use only if no contraindications).

Community‑level interventions

• Indoor residual spraying (IRS) with insecticides.
• Larval source management – eliminating standing water.
• Rapid case detection and treatment to interrupt transmission cycles.

Complications

Although P. malariae is less virulent than P. falciparum, untreated infection can lead to serious sequelae.

• Nephrotic syndrome – Chronic immune complex deposition in glomeruli; presents with edema, proteinuria, and hypoalbuminemia.
• Chronic anemia – Persistent low hemoglobin may require iron supplementation or transfusion.
• Splenomegaly & hypersplenism – Enlarged spleen can cause abdominal discomfort and increased platelet destruction.
• Acute renal failure – Rare but possible during high‑parasitemia bouts.
• Respiratory distress – Usually secondary to severe anemia or co‑existing infections.

Long‑standing infection has also been linked to “blackwater fever” (hemoglobinuria) in rare cases, especially when patients receive certain antimalarial drugs with oxidative potential.

When to Seek Emergency Care

References

• World Health Organization. World Malaria Report 2023. WHO; 2023.
• Centers for Disease Control and Prevention. Malaria: Diagnosis & Treatment. CDC website, accessed June 2026.
• Mayo Clinic. Malaria – Symptoms and causes. Mayo Clinic, 2024.
• Cleveland Clinic. Malaria Treatment Guidelines. Cleveland Clinic, 2025.
• National Institutes of Health. Plasmodium malariae – Clinical features. NIH, 2022.
• Olliaro P, et al. “Non‑falciparum malaria: an overview.” *Lancet Infectious Diseases* 2023;23(5):e150‑e160.